Cargando…
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
BACKGROUND: Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-related adverse events (irAEs) including colitis, dermatitis, and pneumonitis a...
Autores principales: | Shiuan, Eileen, Beckermann, Kathryn E., Ozgun, Alpaslan, Kelly, Ciara, McKean, Meredith, McQuade, Jennifer, Thompson, Mary Ann, Puzanov, Igor, Greer, John P., Rapisuwon, Suthee, Postow, Michael, Davies, Michael A., Eroglu, Zeynep, Johnson, Douglas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319013/ https://www.ncbi.nlm.nih.gov/pubmed/28239462 http://dx.doi.org/10.1186/s40425-017-0210-0 |
Ejemplares similares
-
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy: Endomyocardial Biopsy Provides Pathological Insights to Dual Diseases
por: Serzan, Michael, et al.
Publicado: (2021) -
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
por: Kanz, Bridgette A., et al.
Publicado: (2016) -
Circulating biomarkers to monitor cancer progression and treatment
por: Rapisuwon, Suthee, et al.
Publicado: (2016) -
The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms
por: Hahn, Andrew W., et al.
Publicado: (2023) -
Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
por: Issac, Aaron G., et al.
Publicado: (2022)